Verici Dx plc
VRCDF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.86M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $6.86 Million |
|---|---|
| Enterprise Value | - |
| Earnings per Share | $-0.01 |
| Beta | 1.19 |
| Outstanding Shares | 1,510,428,000 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -0.58 |
|---|---|
| PEG | -0.88 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Last Earnings Call
Report Date
September 14, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Verici Dx plc
19 employees
CEO: Sara jane Barrington
Verici Dx plc is an immuno-diagnostics developer primarily dedicated to innovations within the kidney transplantation field. It creates both prognostic (predictive) and diagnostic (identifying current conditions) assays specifically desi...